ciltacabtagene autoleucel


( Last Updated : September 23, 2022)
Generic Name:
ciltacabtagene autoleucel
Project Status:
Received
Therapeutic Area:
Relapsed or refractory multiple myeloma
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PG0302-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with relapsed or refractory multiple myeloma (RRMM), who previously received at least three prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of patients with relapsed or refractory multiple myeloma (RRMM), who previously received at least three prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody (3L RRMM).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open25-Aug-22
Call for patient/clinician input closed17-Oct-22
Submission received23-Sep-22
Submission accepted